News
NRXPW
0.0126
+137.74%
0.0073
White House shift on psychedelics positive for NRx, says D. Boral
TipRanks · 1d ago
Why Is Vanguard Total Stock Market (VTI) ETF Down Today, 4/20/26?
TipRanks · 1d ago
NRX Pharmaceuticals Price Target Maintained With a $34.00/Share by D. Boral Capital
Dow Jones · 1d ago
NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital
Dow Jones · 1d ago
NRx Pharmaceuticals welcomes the newly-signed Executive Order
TipRanks · 1d ago
NRx Pharmaceuticals Welcomes The Newly-Signed Presidential Executive Order: Accelerating Medical Treatments For Serious Mental Illness
Benzinga · 1d ago
NRx Pharma welcomes Trump order to speed psychedelic drug approvals for mental illness
PUBT · 1d ago
Weekly Report: what happened at NRXP last week (0413-0417)?
Weekly Report · 1d ago
Why Is Vanguard Total Stock Market (VTI) ETF Rising Today, 4/17/26?
TipRanks · 4d ago
Psychedelic: Clearmind’s CMND-100 meets primary endpoint in trial
TipRanks · 5d ago
NRx Pharmaceuticals announces incorporation of NRx Defense Systems
TipRanks · 5d ago
BUZZ-U.S. STOCKS ON THE MOVE-Nike, PNC Financial, Papa John's
Reuters · 6d ago
BUZZ-U.S. STOCKS ON THE MOVE-Gitlab, Snap, Robinhood
Reuters · 6d ago
BUZZ-U.S. STOCKS ON THE MOVE-Broadcom, BofA, Snap
Reuters · 6d ago
BUZZ-NRx Pharmaceuticals rises as it launches defense-focused mental health unit
Reuters · 6d ago
NRx advances robotic TMS plus D-cycloserine neuroplastic therapy for military, responders
PUBT · 6d ago
NRX PHARMACEUTICALS INC: DEVELOPMENT INITIATIVE TO BE CONDUCTED THROUGH R&D UNIT NRX DEFENSE SYSTEMS, IN PARTNERSHIP WITH ZETA SURGICAL
Reuters · 6d ago
NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications
Barchart · 6d ago
NRx Pharmaceuticals appoints Glenn Tyson chief commercial officer
TipRanks · 04/13 11:11
More
Webull provides a variety of real-time NRXPW stock news. You can receive the latest news about Nrx Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About NRXPW
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.